136 related articles for article (PubMed ID: 16904179)
1. Effect of PACAP in 6-OHDA-induced injury of the substantia nigra in intact young and ovariectomized female rats.
Reglödi D; Lubics A; Kiss P; Lengvári I; Gaszner B; Tóth G; Hegyi O; Tamás A
Neuropeptides; 2006 Aug; 40(4):265-74. PubMed ID: 16904179
[TBL] [Abstract][Full Text] [Related]
2. Pituitary adenylate cyclase activating polypeptide protects dopaminergic neurons and improves behavioral deficits in a rat model of Parkinson's disease.
Reglodi D; Lubics A; Tamás A; Szalontay L; Lengvári I
Behav Brain Res; 2004 May; 151(1-2):303-12. PubMed ID: 15084446
[TBL] [Abstract][Full Text] [Related]
3. Morphological and functional effects of PACAP in 6-hydroxydopamine-induced lesion of the substantia nigra in rats.
Reglodi D; Tamás A; Lubics A; Szalontay L; Lengvári I
Regul Pept; 2004 Dec; 123(1-3):85-94. PubMed ID: 15518897
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of the effects of PACAP in young, aging, and castrated males in a rat model of Parkinson's disease.
Reglódi D; Tamás A; Lengvári I; Toth G; Szalontay L; Lubics A
Ann N Y Acad Sci; 2006 Jul; 1070():518-24. PubMed ID: 16888218
[TBL] [Abstract][Full Text] [Related]
5. Age and gender differences in behavioral and morphological outcome after 6-hydroxydopamine-induced lesion of the substantia nigra in rats.
Tamás A; Lubics A; Szalontay L; Lengvári I; Reglodi D
Behav Brain Res; 2005 Mar; 158(2):221-9. PubMed ID: 15698888
[TBL] [Abstract][Full Text] [Related]
6. KDI tripeptide of gamma1 laminin protects rat dopaminergic neurons from 6-OHDA induced toxicity.
Väänänen AJ; Rauhala P; Tuominen RK; Liesi P
J Neurosci Res; 2006 Aug; 84(3):655-65. PubMed ID: 16810683
[TBL] [Abstract][Full Text] [Related]
7. Pituitary adenylate cyclase-activating polypeptide (PACAP) has a neuroprotective function in dopamine-based neurodegeneration in rat and snail parkinsonian models.
Maasz G; Zrinyi Z; Reglodi D; Petrovics D; Rivnyak A; Kiss T; Jungling A; Tamas A; Pirger Z
Dis Model Mech; 2017 Feb; 10(2):127-139. PubMed ID: 28067625
[TBL] [Abstract][Full Text] [Related]
8. Effect of intrastriatal 6-OHDA lesion on dopaminergic innervation of the rat cortex and globus pallidus.
Debeir T; Ginestet L; François C; Laurens S; Martel JC; Chopin P; Marien M; Colpaert F; Raisman-Vozari R
Exp Neurol; 2005 Jun; 193(2):444-54. PubMed ID: 15869947
[TBL] [Abstract][Full Text] [Related]
9. Pigment epithelium derived factor (PEDF) is neuroprotective in two in vitro models of Parkinson's disease.
Falk T; Zhang S; Sherman SJ
Neurosci Lett; 2009 Jul; 458(2):49-52. PubMed ID: 19442875
[TBL] [Abstract][Full Text] [Related]
10. Bilobalide inhibits 6-OHDA-induced activation of NF-kappaB and loss of dopaminergic neurons in rat substantia nigra.
Li LY; Zhao XL; Fei XF; Gu ZL; Qin ZH; Liang ZQ
Acta Pharmacol Sin; 2008 May; 29(5):539-47. PubMed ID: 18430361
[TBL] [Abstract][Full Text] [Related]
11. Baicalein exerts neuroprotective effects in 6-hydroxydopamine-induced experimental parkinsonism in vivo and in vitro.
Mu X; He G; Cheng Y; Li X; Xu B; Du G
Pharmacol Biochem Behav; 2009 Jun; 92(4):642-8. PubMed ID: 19327378
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotective effect of BDNF in young and aged 6-OHDA treated rat model of Parkinson disease.
Singh S; Ahmad R; Mathur D; Sagar RK; Krishana B
Indian J Exp Biol; 2006 Sep; 44(9):699-704. PubMed ID: 16999024
[TBL] [Abstract][Full Text] [Related]
13. Effects of pituitary adenylate cyclase activating polypeptide in a rat model of traumatic brain injury.
Farkas O; Tamás A; Zsombok A; Reglodi D; Pál J; Büki A; Lengvári I; Povlishock JT; Dóczi T
Regul Pept; 2004 Dec; 123(1-3):69-75. PubMed ID: 15518895
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice.
Alvarez-Fischer D; Henze C; Strenzke C; Westrich J; Ferger B; Höglinger GU; Oertel WH; Hartmann A
Exp Neurol; 2008 Mar; 210(1):182-93. PubMed ID: 18053987
[TBL] [Abstract][Full Text] [Related]
15. Effect of 6-hydroxydopamine treatment on kynurenine aminotransferase-I (KAT-I) immunoreactivity of neurons and glial cells in the rat substantia nigra.
Knyihár-Csillik E; Chadaide Z; Mihály A; Krisztin-Péva B; Fenyo R; Vécsei L
Acta Neuropathol; 2006 Aug; 112(2):127-37. PubMed ID: 16788821
[TBL] [Abstract][Full Text] [Related]
16. Postural changes after lesions of the substantia nigra pars reticulata in hemiparkinsonian monkeys.
Henderson JM; Stanic D; Tomas D; Patch J; Horne MK; Bourke D; Finkelstein DI
Behav Brain Res; 2005 May; 160(2):267-76. PubMed ID: 15863223
[TBL] [Abstract][Full Text] [Related]
17. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease.
Aponso PM; Faull RL; Connor B
Neuroscience; 2008 Feb; 151(4):1142-53. PubMed ID: 18201835
[TBL] [Abstract][Full Text] [Related]
18. Changes in PACAP levels in the central nervous system after ovariectomy and castration.
Nemeth J; Tamas A; Jozsa R; Horvath JE; Jakab B; Lengvari I; Arimura A; Lubics A; Reglódi D
Ann N Y Acad Sci; 2006 Jul; 1070():468-73. PubMed ID: 16888211
[TBL] [Abstract][Full Text] [Related]
19. G-CSF protects dopaminergic neurons from 6-OHDA-induced toxicity via the ERK pathway.
Huang HY; Lin SZ; Kuo JS; Chen WF; Wang MJ
Neurobiol Aging; 2007 Aug; 28(8):1258-69. PubMed ID: 16839644
[TBL] [Abstract][Full Text] [Related]
20. Enriched environment induces cellular plasticity in the adult substantia nigra and improves motor behavior function in the 6-OHDA rat model of Parkinson's disease.
Steiner B; Winter C; Hosman K; Siebert E; Kempermann G; Petrus DS; Kupsch A
Exp Neurol; 2006 Jun; 199(2):291-300. PubMed ID: 16360152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
